Even if the risk of developing breast cancer is low or moderate for most patients, screening might be advisable if BAP1-deficient breast cancers are confirmed to be associated with poor prognosis and/or warrant specific therapeutic approaches. Here, BAP1 is linked to breast carcinoma.